Drugs / Plasma-Activated Saline Solution
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07272603 | Dec 2025 → Feb 2026 overdue | bladder transitional cell carcinoma | Qilu Hospital of Shandong University | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Plasma-Activated Saline Solution | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07272603 ↗ |
| Known as | PASS | “The intervention involves the use of Plasma-Activated Saline Solution (PASS), a liquid infused with reactive oxygen and nitrogen species (RONS) created by exposing standard...” NCT07272603 ↗ |
| Modality | Other / unclassified | “The intervention involves the use of Plasma-Activated Saline Solution (PASS), a liquid infused with reactive oxygen and nitrogen species (RONS) created by exposing standard...” NCT07272603 ↗ |
| Route | Other | “Participants will receive intravesical (into the bladder) instillations of PASS every other day for one week, with each instillation retained for approximately one hour.” NCT07272603 ↗ |